D-Wave Quantum Stock Is Up Over 200% Over the Last Year. Time to Buy?

D-Wave Quantum delivered just under $22 million of revenue in the first nine months of 2025 (up ~235% year-over-year) but widened its net loss to $313 million versus a $58 million loss a year earlier, including a $260 million fair-value change on warrant liabilities and higher operating expenses. The company had $836 million of liquidity and negative free cash flow of $56 million through nine months; its stock has rallied roughly 380% over the past 12 months and trades at an implied price-to-sales ratio above 350 despite forecasted revenue growth of ~190% for 2025 and 55% for 2026, leading the author to conclude the valuation is disconnected from fundamentals and the shares remain highly speculative.

Analysis

Market structure: D-Wave (QBTS) is the short-term beneficiary of bullish quantum sentiment and any enterprise optimization wins (customers, cryo/chip suppliers, cloud partners), while speculative late entrants and retail momentum buyers are the most exposed if re-rating occurs. Pricing power is limited — buyers of commercial quantum cycles will negotiate on trials and services — so scalable revenue depends on converting pilot projects into multi-year ARR rather than one-off system sales.

Risk assessment: Key tail risks are a second large non-cash adjustment to warrant liabilities (repeat of the $260M hit), a dilutive financing or failed commercial traction, or a competing gate-model or classical algorithm leap; each could cause >50% downside within 12 months. Immediate risk (days/weeks) is elevated IV and momentum; short-term (3–12 months) hinges on next quarterly revenue/ARR and cash burn; long-term (12–36 months) depends on sustained positive FCF and enterprise adoption metrics.

Trade implications: For capital efficiency, favor asymmetric hedges: buy 90–180 day ATM puts sized to risk 1–2% of portfolio, and size a speculative 24‑month LEAP call allocation ≤0.5% as a lottery ticket if you want upside exposure. Pair trades: overweight NVDA (NVDA) by 3–5% of portfolio for secular compute demand while shorting QBTS 1–2% (or via puts) to isolate quantum hype vs. real semiconductor demand; take profits on either leg after 30–50% move or fundamental catalyst resolution.

Contrarian angles: Consensus misses that QBTS can either crater (forced dilution, warrant shocks) or be acquired/partnered by a large cloud/semiconductor player — both high-conviction but low-probability outcomes. Mispricing exists in tail-risk spreads: implied volatility likely overstates near-term fundamental upside but understates a transformational acquisition scenario; use tight, size‑constrained option positions rather than outright directional exposure.

Key Decisions for Investors

• Establish a tactical hedge: buy QBTS 90–180 day ATM puts sized so maximum premium risk = 1% of portfolio; take profits if puts gain 50% or if QBTS falls 30–40%; exit if company reports sustained positive FCF guidance or cash runway >24 months.
• Initiate a paired allocation: overweight NVDA by +3–5% of portfolio (buy shares or 6–12 month call spreads) and short QBTS exposure = 1–2% (via stock or puts). Hold 6–12 months; use 20% trailing stop on NVDA and cover short QBTS if QBTS revenue growth guidance exceeds +100% YoY and recurring revenue >$50M.
• Buy optionality as a long-shot: allocate ≤0.5% of portfolio to QBTS 18–24 month LEAP calls (1.5–2x current strike) as asymmetric upside exposure; cap total quantum-spec capital at <5% of tech allocation to limit dilution risk.
• Avoid establishing a >1% outright long in QBTS until two concrete triggers are met: (A) quarterly free cash flow turns positive or negative FCF < $100M over trailing 12 months, and (B) share count dilution risk is cleared (no large warrant revaluation or announced financing within 90 days).